Clinical Trial Update: Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for VB-111 in recurrent glioblastoma multiforme (Phase 1/Phase 2) completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma Multiforme

Drugs mentioned

• VB-111

Snippet

Sponsor: Vascular Biogenics Ltd. operating as VBL Therapeutics | Conditions: Glioblastoma Multiforme | Phase 1, Phase 2 | Status: COMPLETED